Disclosed are a nimodipine injection composition and preparation method therefor. The nimodipine injection composition includes the following components in parts by mass concentration: 0.02-0.23% of nimodipine, 2-30% of oil for injection, 0.8-3% of emulsifier, 0-0.1% of complexing agent, 0-0.3% of stabilizer, 1-3% of osmotic pressure adjusting agent. The composition does not contain solubilizers such as ethanol, auxiliary emulsifiers such as tween-80, and cosolvents such as benzyl alcohol.

Disclosed are a nimodipine injection composition and preparation method therefor. The nimodipine injection composition includes the following components in parts by mass concentration: 0.02-0.23% of nimodipine, 2-30% of oil for injection, 0.8-3% of emulsifier, 0-0.1% of complexing agent, 0-0.3% of stabilizer, 1-3% of osmotic pressure adjusting agent. The composition does not contain solubilizers such as ethanol, auxiliary emulsifiers such as tween-80, and cosolvents such as benzyl alcohol.

A single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia is provided. Stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

A single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia is provided. Stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

A single dosage form of pharmaceutical composition for treatment of hypertension and hyperlipidemia is provided. Stability and uniform dissolution rates of drugs may be ensured by mixing compositions containing desired drugs and formulating the mixture into a single compartment form, whereby a manufacturing process becomes simple while reducing processing costs. Further, a formulation having biological equivalence to conventional single formulations may be obtained.

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

The use of oral colchicine solutions in combination with other therapeutics, while minimizing toxic drug to drug interactions are described herein. Related compositions are also provided.

The present invention relates to pharmaceutical combination for use in the treatment and/or prevention of diabetes, comprising a calcium channel blocking agent and an incretin.

The present invention relates to pharmaceutical combination for use in the treatment and/or prevention of diabetes, comprising a calcium channel blocking agent and an incretin.

Provided herein is a coated particle comprising: (i) a microparticle that comprises a pharmaceutically acceptable excipient and (ii) nanoparticles of a therapeutic agent, wherein the surface of the microparticle is coated with the nanoparticles. Also provided herein is a pharmaceutical composition comprising the coated particle. Furthermore, provided herein are methods of their preparation.